Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Baxano Surgical Inc. (NASDAQ: BAXS) shares surged 10.72 percent to close at $1.14 a share Thursday. The stock traded between $1.11 and $1.23 on volume of 3.92 million shares traded. The company announced that it has received FDa 510(k) clearance for its Avance™ MIS Pedicle Screw System. Shares of Baxano Surgical are up approximately 13.0 percent year-to-date.
Get more information on Baxano Surgical and free access to the in-depth equity report at: www.FiveStarEquities.com/BAXS
3D Systems Corporation (NYSE: DDD) shares declined 10.79 percent to close at $48.78 a share Thursday. The stock traded between $48.51 and $54.88 on volume 8.43 million shares traded. The company recently announced the immediate availability of the Sense™ 3D scanner for Mac and feature upgrades available with Sense software V1.1. Shares of 3D Systems have fallen approximately 48.0 percent year-to-date.
Get more information on 3D Systems and free access to the in-depth equity report at: www.FiveStarEquities.com/DDD
Box Ships Inc. (NYSE: TEU) shares dropped 20.17 percent to close at $1.90 a share Thursday. The stock traded between $1.84 and $1.98 on volume of 3.15 million shares traded. The company announced the pricing of public offering of 5.0 million units and warrants at $2.05 per units. Shares of Box Ships are down approximately 42.0 percent year-to-date.
Get more information on Box Ships and free access to the in-depth equity report at: www.FiveStarEquities.com/TEU
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares fell 11.09 percent to close at $14.03 a share Thursday. The stock traded between $13.93 and $15.90 on volume 1.37 million shares traded. The company has recently announced the availability of HETLIOZ a treatment for Non-24-Hour Sleep-Wake Disorder. Shares of Vanda Pharmaceuticals are up approximately 13.0 percent year-to-date.
Get more information on Vanda Pharmaceuticals free access to the in-depth equity report at: www.FiveStarEquities.com/VNDA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]